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ABSTRACT  
In spite of advanced chemotherapy and radiotherapy the term Cancer 
still induces fear of death in common man. Cancers figure among the 
leading causes of morbidity and mortality worldwide, with 
approximately 14 million new cases and 8.2 million cancer related deaths 
(2012). Generally in the women, the five most common sites of cancer are 
breast, colorectum, lung, cervix, and stomach. But, the most common 
types of gynaecologic malignancies are cervical cancer, ovarian cancer, 
and endometrial (uterus) cancer etc. On par with other cancers, 
Gynecological cancers also contribute to significant number of deaths. In 
India alone, among the gynaecological cancers, breast cancer accounts for 
21.5% deaths; cervical cancer for 20.7% deaths, ovarian cancer for 6.0% 
of deaths (World Health Organization - Cancer Country Profiles, 2014). 
The main goals of a cancer diagnosis and treatment programme are to 
cure or considerably prolong the life of patients and to ensure the best 
possible quality of life to cancer survivors. Ayurveda plays a key role in 
prevention; prolong the life span and improvement of quality of life in 
cancer. In the direction of prevention of cervical carcinoma, poly-herbal 
compounds ‘Praneem’ and ‘Basant’ are studied extensively. To improve 
the quality of life, CCRAS have been initiated trials with coded drug 
AYUSH-QOL-2C, in non-metastatic breast cancer patients those who are 
receiving chemotherapy/radio-therapy, at St. Johns medical college, 
Bangalore, Karnataka. Some other clinical studies are also carried out to 
see the effect of turmeric as an adjuvant in abroad. Apart from the clinical 
trials number of single herbal drugs like Haridra, Bhallataka, 
Ashvagandha etc., and compound herbo-mineral preparations are studied 
to see their efficacy on different types of gynaecological cancers. In united 
states of America, clinical trials on arsenic preparations are also carried 
out. Present article aims to review the usefulness of these drugs in 
Gynecological cancers and their safety too. 
 
INTRODUCTION 
 Cancer is a malignant growth or tumour 
resulting from an uncontrolled division of cells. 
Cancers figure among the leading causes of 
morbidity and mortality worldwide, with 
approximately 14 million new cases and 8.2 million 
cancer related deaths (W.H.O). Gynecological 
cancers are among the most common cancers in 
women and became an important public health 
issue. Top five cancers seen in Indian women are 
breast cancer, ovarian cancer, colo-rectal cancer, 
ovarian cancer and lip/oral cancers. Ovarian cancer 
has emerged as one of the most common 
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malignancies affecting women in India and has 
shown an increase in the incidence rates over the 
years. Although cervical cancer is on a declining 
trend, it remains the second most common cancer 
in women after breast cancer.1 
 In India, every year 122,844 women are 
diagnosed with cervical cancer and 67,477 die from 
the same. India has a population of 432.2 million 
women (age 15 & older) at the risk of developing 
cancer. In the women aged between 15-44 years, 
cervical cancer is the second most common cancer 
in India. Therefore, prevention of cervical cancer is 
very vital in regard to Indian women2.  
 One woman dies of cervical cancer at every 
eight minutes in India3. For every two women 
newly diagnosed with breast cancer, one woman 
dies of it in India4,5,6. Cervical and breast cancer in 
females accounts for over 50% of all cancer deaths 
in India7. Breast cancer is the most common cancer 
in women in India and accounts for 27% of all 
cancers in women8. The incidence rates in India 
begin to rise in the early thirties and peak at ages of 
50-64 years9. Cervical cancer is the third largest 
cause of cancer mortality in India accounting for 
nearly 10% of all cancer related deaths in the 
country10.  
 Economic burden of cancer: Cancer has 
deep economic and social impact on the people who 
are suffering from cancer. Often Cancer treatment 
pushes the families to below poverty line and 
threatens social security. The International Agency 
for Research on Cancer GLOBOCAN project11 has 
predicted that India’s cancer burden will nearly 
double in the next 20 years, from slightly over a 
million new cases in 2012 to more than 1·7 million 
by 2035. This upward trend of Gynecological 
cancers may be partially due to emergence of India 
as a fast growing economy with changes in lifestyle-
related behaviour over the past twenty years.  
 In Ayurvedic science also there is 
description about the cancer like conditions of 
reproductive tract. In Carakasamhita and Sushruta 
samhita these are described under the Yonivyapad, 
Artavavyapat, Raktapradara, Arbuda etc. Based on 
the descriptions of symptoms and signs of the 
disease condition, the following conditions can be 
compared with Gynecological cancers - Kunapa-
granthi artavadushti, Granthibhuta artavadushti, 
Sannipataja pradara, Rakta arbuda, Mamsa arbuda 
etc. Kunapagandhi artava dushti manifests with 
heavy bleeding per vagina with the smell of a dead 
body. This description indicates the early stages of 
endometrial carcinoma, and this condition 
described as incurable12.  
 In Granthibhuta artavadushti, menstrual 
bleeding is appears like Granthi (clotted 
appearance); this condition is also described as 
incurable. Based on the presenting clinical features 
this can be compared with early stages of 
endometrial carcinoma13. Mutrapurisha-gandhi 
artavadushti presents as bleeding per vagina having 
smell of urine and faeces; is incurable. This 
condition is possible when menstrual blood is 
mixed with urine and faeces. This usually happens 
when there is formation of vesico vaginal or 
rectovaginal fistulas are formed. These fistula are 
formed in the advanced stages of malignancies of 
vagina, cervix etc. This condition is described as 
incurable14.  
 There is another clinical condition 
described by Sushruta under Asrugdara called 
Sannipataja asrugdara, clinically presents with 
excessive bleeding per vagina having the 
characteristics of vitiation of all three humours, 
menstrual blood resembles like Kanji (sour gruel) in 
colour and has foul smell. Vagbhata described that 
in this condition blood colour appears blue like 
bronze, dirty and has foul smell. Putrid or foul smell 
and bleeding in different colours are the features of 
cervical or endometrial cancers15.  
 In Ayurveda all benign tumours are 
described under the heading Arbuda and some 
varieties of these tumours are described as 
incurable like Raktarbua, Mamsarbuda. Raktarbuda 
is a fast growing tumour, presents with vitiated 
bloody discharge. Mamsarbuda presents a painless, 
stony hard, smooth, fixed swelling, which never 
suppurates. Both these Arbuda are labelled as 
incurable. Based on the clinical features, both of 
these tumours can be considered as Malignancies16.  
The main goals of cancer diagnosis and 
treatment programme are to cure or considerably 
prolong the life of patients and to ensure the best 
possible quality of life to cancer survivors. 
Prevention is really the best thing with respect to 
cancer; in this regard Ayurveda can play a major 
role. Prolonging the life span and improvement of 
quality of life is the second goal of treatment. In 
addition to this Ayurvedic drugs can also helps in 
reducing the side effects of chemo/radio therapy 
and enhance the efficacy of same drugs.  
 Aim of the article: Main aim of this article is 
to review the effectiveness of the Ayurvedic herbal 
and herbo-mineral preparations in the prevention, 
management of gynaecological cancers.  
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Estimated worldwide cancer mortality in women (Courtesy WHO 2015) 
Prevention of Cancers 
 Carcinoma cervix is a major problem 
causing death of 510,000 women every year 
worldwide. A virus HPV (Human papilloma virus 
specially strains 16 and 18) infection of cervix 
initiates the transformation of cervical cells from 
normal to malignant cells. This transformation is a 
slow process and goes through various stages 
known as cervical intraepithelial neoplasia with 
stages CIN-1 CIN-2 and CIN-3. This transformation 
can be reversed to normal stage. 
 A clinical trial was carried out with the aim 
of elimination of HPV-16 in women with early 
Cervical Intraepithelial Lesions. Trial taken with a 
polyherbal cream called ‘Basant’; containing 95% 
pure diferuloyl methane (E,E)-1,7-bis (4-hydroxy-3-
methoxyphenyl)-1,6-heptadiene-3,5-dione), 
(Curcumin) from Curcuma longa, purified extracts 
of Emblica officinalis, Neem (Azadirachta indica) 
leaves, and Aloe vera (Aloe barbadensis). This drug 
was administered for 30 days as intra-vaginal 
tablets. Women enrolled were in reproductive age 
group (25 - 45 years), employing contraceptives, 
had regular monthly menses every 21 - 35 days, or 
amenorrhea due to hormonal contraceptive use, 
and were agreeable to abstain from non-steroidal 
anti-inflammatory drugs (NSAIDS) during the study 
period.  
 Women having suspicious lesions, and 
having persistent vaginal discharge were also 
included. Women who have undergone total 
hysterectomy, or are using intrauterine 
contraceptive device (IUCD) as a form of birth 
control method and who are pregnant or lactating 
were excluded from the study. Patients enrolled for 
this study were assigned alternatively to receive 
either intravaginal capsules of BASANT, two 
capsules (250 mg each) each night or two Placebo 
capsules for 30 days, excluding the days of 
menstrual period and they were evaluated for the 
presence or absence of HPV16 in cervical cells by 
generic and type specific PCR. 
 HPV DNA presence or absence was tested as 
primary outcome. Pap smear, visual inspection and 
colposcopic examination of the cervix were carried 
out before and after the treatment, to study the 
effect of treatment on the lesion and on cytology as 
outcome. Out of 35 subjects enrolled, 19 patients 
were found positive for HPV-16. Only 11 out of 
these 19 agreed to undergo intravaginal treatment 
with BASANT. After 30 days of intravaginal 
insertion of BASANT, all eleven HPV-16 positive 
cases became HPV negative.17, 18 
 Another study carried out by team of 
scientists from Division of Molecular Oncology; 
Division of Cytopathology, Division of Clinical 
Oncology of Institute of Cytology and Preventive 
Oncology (ICMR), Noida and Department of 
Obstetrics and Gynecology, Lok Nayak Hospital, 
New Delhi on Cervical Pre-cancerous lesions. They 
have developed a polyherbal formulation called 
'Praneem', and carried out a study to evaluate the 
potential of anti-HPV activity of Praneem in women 
infected with high risk HPV type 16. Study was 
carried out on twenty women who were 
molecularly diagnosed as positive for HPV16 
infection without or with low grade squamous 
intraepithelial lesion (LSIL) or inflammation and 
assigned to intra-vaginal, topical application of 
either Praneem tablet or placebo for 30 days 
excluding the days of menstrual period and were 
evaluated for persistence of HPV infection using 
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HPV L1 consensus and HPV type 16-specific PCR as 
primary outcome.  
 In 6 out of 10 (60%) women, after one 
course of Praneem treatment, HPV was eliminated. 
A repeated treatment in remaining four patients 
with persisting HPV infection, resulted in clearance 
of HPV in two additional cases; and this resulted in 
an overall 80% clearance of HPV 16 as against a 
spontaneous clearance of 10% (1/10) seen in the 
placebo arm. The elimination of HPV DNA was 
found to be accompanied by marked improvement 
in clinical symptoms and cytological abnormalities 
of Praneem-treated patients. Finally the result 
showed that a 30-day intra-vaginal application of 
the Praneem can result in elimination of HPV 
infection from the uterine cervix. A disadvantage of 
Praneem was the irritation that was observed in 
some subjects19.  
 A pilot study carried out as integrative 
therapy on Low-grade Squamous Intra-epithelial 
Lesion persistent after antimicrobial treatment and 
treated with oral administration of a standardized 
extract of Turmeric Oil (coded as NBFR-03). A total 
of 1473 women were screened through Papsmear, 
among those 88 cases had Low-grade Squamous 
Intra-epithelial Lesion. Among these women, only 
those having persistent Low-grade Squamous Intra-
epithelial Lesion subsequent to antimicrobial 
therapy, and willing to follow the protocol (N=21), 
were included in the study. Clinical examination, 
Pap smears, colposcopy, clinical biochemistry, 
urinalysis and assessment of serum IL-6, were 
carried out before and after treatment. 
Standardised NBFR-03 (0.2gm) capsules were 
administered, twice daily, for 12 weeks. Out of 21, 
19 women completed the study, in none of the case 
pathology progressed further and 16 cases shown 
regression to Atypical or Negative smears20.  
Improvement of Quality of life in Cancer 
patients 
 Some research studies are carried out for 
improvement in quality of life in cancer patients. 
Central Council for Research in Ayurvedic Sciences, 
an apex body of research in Ayurveda developed 
AYUSH-QOL -2C a coded drug and taken up 
collaborative study in the patients those who 
receive chemotherapy/radio-therapy in cases of 
breast cancer with St. Johns medical college, 
Bangalore. This was a Randomized Double Blinded 
Placebo Controlled trial, and executed at St. Johns 
Medical College and Hospital to assess the efficacy 
and safety and to evaluate Quality of Life with 
Ayush QOL 2C in patients of Non Metastatic Breast 
Cancer as a supplement to adjuvant Chemotherapy. 
Dose of the trial drug two capsules twice in a day 
for 6 months in 80 patients diagnosed to have 
breast cancer and are operated for the same and are 
receiving chemotherapy of 4 or 8 cycles. The 
Primary outcome of the study was efficacy of 
AYUSH QOL 2C in improvement in quality of life in 
comparison to placebo. Secondary outcome was 
safety of AYUSH QOL 2C as a supplement to 
adjuvant chemotherapy during each cycle and at 
sixth month, ninth month and at the end of one 
year. The assessment of efficacy of patients was 
carried out using Visual Analogue Scale, FACT-B 
(Functional Assessment of Cancer Therapy 
Questionnaire for Breast Cancer) and ECOG 
(Eastern Cooperative Oncology Group) scale as well 
as hematological, biochemical and clinical 
examination was adopted to report on severity of 
toxicity experienced by patients on oncology 
treatment trials. This trial is completed but, results 
not yet published21.  
Note: VAS –Visual Analogue Scale - is commonly 
used to rate various subjective experiences; in 
cancer patients it is used to analyse the quality of 
life; QOL scores may reflect physical or psychosocial 
functioning or distress. 
FACT-B – Functional Assessment of Cancer Therapy 
Questionnaire for Breast Cancer, Breast Cancer 
Chemotherapy Questionnaire developed to measure 
outcomes of women with stage II breast cancer 
receiving adjuvant chemotherapy.  
ECOG: Eastern Cooperative Oncology Group 
(ECOG PS) - is used by physicians to report on 
severity of toxicity experienced by patients on 
oncology treatment trials. The ECOG measures 
toxicity effects on a five-point scale with 0 being 
“fully active, able to carry on all pre-disease 
performance without restriction” and 5 indicating 
that the patient is deceased.22 
Clinical trials on Adjuvant therapy 
 A Study carried out to see the feasibility and 
tolerability of the combination of docetaxel and 
curcumin, a polyphenolic derivative extracted from 
Curcuma longa as an adjuvant therapy on Patients 
with advanced or metastatic breast cancer. 
Docetaxel (100 mg/m2) was administered as a 1-
hour I.V. infusion every 3 weeks on d1 for 6 cycles. 
Docetaxel is an antineoplastic agent that acts by 
disrupting the microtubular network in cells that is 
essential for mitotic and interphase cellular 
functions. Curcumin was orally given from 500 
mg/d for 7 consecutive days by cycle (from d-4 to 
d+2) and escalated until a dose-limiting toxicity 
should occur. 
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 The primary endpoint of this study was 
determination of the maximal tolerated dose of the 
combination of dose-escalating curcumin and 
standard dose of docetaxel chemotherapy in 
advanced and metastatic breast cancer patients. 
Secondary objectives included are toxicity, safety, 
vascular endothelial growth factor and tumor 
markers measurements, and assessment of 
objective and clinical responses to the combination 
therapy. 
 Results observed was - at the last dose level 
of curcumin, 3 dose-limiting toxicities were 
observed and 2 out of 3 patients at this dose level 
refused to continue treatment; this led the 
researchers to define the maximal tolerated dose of 
curcumin at 8000 mg/d. The efficacy of the drug 
was enhanced. The recommended dose of curcumin 
is 6000 mg/d for 7 consecutive days every 3 weeks 
in combination with a standard dose of docetaxel23.  
 Another study was carried out to assess the 
ability of the Curcumin to reduce radiation 
dermatitis severity in 30 breast cancer patients. 
Designs of the study was randomized, double-blind, 
placebo-controlled clinical trial. In this study adult 
female with non-inflammatory breast cancer or 
carcinoma in situ prescribed radiotherapy without 
concurrent chemotherapy were included. 
Randomized patients took 2.0 grams of curcumin 
(trial group) or placebo orally three times per day 
(i.e. 6.0 grams daily) throughout their course of 
radio therapy. Assessments were done every week 
based on Radiation Dermatitis Severity (RDS) score, 
presence of moist desquamation, redness 
measurement, McGill Pain Questionnaire-Short 
Form and Symptom Inventory questionnaire. The 
30 evaluable patients were primarily white (90%) 
and had a mean age of 58.1 years.  
 Standard pooled variances t test carried out, 
it showed that curcumin reduced RDS at end of 
treatment compared to placebo (mean RDS = 2.6 vs. 
3.4; P = 0.008). Fisher's exact test revealed that 
fewer curcumin-treated patients had moist 
desquamation (28.6% vs. 87.5%; P = 0.002). No 
significant differences were observed between arms 
for demographics, compliance, radiation skin dose, 
redness, pain or symptoms. In conclusion, oral 
curcumin, 6.0 g daily during radiotherapy, reduced 
the severity of radiation dermatitis in breast cancer 
patients.24 
Herbal drugs 
A). Haridra - Curcuma longa: So far no known 
pharmaceutical drug effectively prevents breast 
cancer metastasis. However, new research from the 
M.D. Anderson Cancer Center at the University of 
Texas in Houston suggests that consuming 
adequate amounts of the common spice curcumin 
may halt the spread of breast cancer in its tracks25. 
Curcuma also exhibited number of anticancer 
activities on pharmacological studies. Curcumin’s 
inhibition of breast cancer metastasis in the new 
mouse study appears to rest on its ability to 
suppress a substance called nuclear factor kappa B 
(NF-?B). Other activities found are - promotion of 
apoptosis, potentiating the effects of other forms of 
chemotherapy, inhibiting angiogenesis.  
 In another well-controlled clinical trial, 
patients with various high-risk premalignant 
lesions took curcumin for three months at daily 
doses ranging from 1 g to 12 g. Improvement in the 
lesions was noted in one of four patients with 
uterine cervical intraepithelial neoplasm, a 
precancerous condition of the uterine cervix. Most 
importantly, there was absolutely no toxicity in 
these patients at doses up to 8 g per day. While 
the 12 g dose was also nontoxic, it was deemed 
unacceptable because the volume of curcumin was 
so large.26 
B). Bhallataka - Semicarpus anacardium 
 This drug was studied extensively for its 
Anti-carcinogenic activity in the Department of 
Shalyatantra, Institute of medical sciences, Benarus 
Hindu University, Varanasi as an adjuvand drug. 
Extensive pharmacological screening of this drug 
also been done by many allied scientists worldwide.  
 Mathivadhani et al. studied Bhallataka nut 
extract for inhibitory effect on human breast cancer 
cells (T47D). Cytotoxicity analyses suggested that 
these cells had become apoptotic. Semecarpus 
anacardium was discovered to induce rapid Ca(2+) 
mobilization from intracellular stores of T47D cell 
line, and its cytotoxicity against T47D was well 
correlated with altered mitochondrial trans-
membrane potential. At the molecular level, these 
changes are accompanied by decrease in Bcl(2) and 
increase in Bax, cytochrome c, caspases and PARP 
cleavage, and ultimately by internucleosomal DNA 
fragmentation. Results of this study provided 
unprecedented evidence that Bhallataka triggers 
apoptotic signals in T47D cells27.  
 Another study carried out with two groups, 
first group with ‘Kalpamruta’ (KA) containing 
Semicarpus anacardium as main ingredient; second 
group with plain Semicarpus anacardium (SA) in 
breast cancer induced rats. Kalpaamruthaa (KA) is a 
modified Siddha preparation, which contains 
Semecarpus anacardium Linn., Emblica officinalis 
and honey. The study carried out to assess the 
variations in lipids, lipid-metabolizing enzymes and 
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lipoproteins in cancerous animals and the effect of 
KA on the lipid metabolism. The effects of first 
group (KA) were found to be more effective than 
second group (SA). No significant alterations were 
observed in herbal preparation control animals 
when compared to control animals28. 
C. Ashwagandha – Withania somnifera 
 Ashwagandha considered as the king of the 
medicinal plants, is also studied extensively for its 
different pharmacological actions. A study carried 
out the leaf extract of this drug for its anti-
proliferative activity on MCF-7 (breast) human 
tumor cell lines. Compounds 1-12 and diacetyl 
withaferin A were shown to produce anti-
proliferative activity on MCF-7 (Breast) human 
tumor cell lines29. Withaferin A has been found to 
inhibit growth of MCF-7 and MDA-MB-231 human 
breast cancer cells in culture and MDA-MB-231 
xenografts in vivo by causing apoptosis30.  
 A novel bioactive compound withanolide 
sulfoxide obtained from methanol extract of 
Withania Somnifera roots has been shown to 
suppress human tumor cell proliferation and its 
IC50 value against human breast (MCF-7) cancer 
cell lines in the range of 0.74-3.63µm31. 
D. Rohitaka/Rohituka - Amoora rohituka 
 This plant also studied extensively in the 
Department of Shalyatantra, Institute of Medical 
Sciences, Benarus Hindu University for its ante-
cancer activities. Triterpenic acid, amooranin, 
extracted from the bark of Amoora rohituka trees, 
has been reported to possess significant anticancer 
potential32. Amooranin has been shown to induce 
apoptosis in breast carcinoma through caspase 
activity33.  
E. Devadaru –Cedrus deodara 
 In vitro cytotoxicity studies showed 
significant dose-dependent effects against several 
cancer cell lines from different tissues such as 
breast, cervix, neuroblastoma, colon, liver, and 
prostate at 10, 30 and 100 microg/mL. The IC (50) 
values varied from 16.4 ng/mL to 116.03 
microg/mL depending on the cell line34.  
Apart from the above, some other medicinal plants 
are also found effective on pharmacological studies 
in Gynecological cancers. Details are given below: 
 Ipomoea squamosa - Ovarian cancer  
 Curculigo orchioides - Breast cancer 
 Citrullus colocynthis - Breast cancer 
 Semecarpus anacardium - Breast adeno 
carcinoma, cervical epithelial carcinoma 
 Berberis vulgaris - Breast cancer 
 Bidens pilosa - Cervix cancer 
 Ocimum gratissimum - Breast cancer 
Mineral drug – Arsenic trioxide 
 Arsenic trioxide is a chemotherapy drug 
treatment for acute promyelocytic leukaemia (APL). 
Arsenic trioxide is found to inhibit growth and 
promotes apoptosis in many different cancer cell 
lines. The National Cancer Institute (US) is working 
cooperatively with research centers across the U.S. 
to evaluate its clinical activity in hematologic 
malignancies - such as acute promyelocytic 
leukemia, acute myeloid leukemia, etc., and multiple 
myeloma. It is also supporting research in solid 
tumors, such as advanced hormone-refractory 
prostate cancer and renal cell cancer and in cervical 
cancer and refractory transitional cell carcinoma. 
US Brand name for Arsenic trioxide is Trisenox and 
is approved by FDA.  
 A study carried out at Memorial Sloan-
Kettering Cancer Center with focus on patients with 
advanced cervical cancer; showed that arsenic 
trioxide induces apoptosis in HPV 16 DNA-
immortalized human cervical epithelial cells in vitro 
and selectively inhibits early viral gene 
expression35. Inclusion of arsenic in the media 
proved cytotoxic for a variety of cell lines, including 
those for bladder and cervical cancers36. Based on 
these trials on Arsenic oxide, Ayurveda people can 
also take up trials with Bhasmas of Gouripashana, 
Manahshila and Haratala, since these are the ores of 
arsenic.  
Compound drug 
 Ayurvedic compound drug containing 
Semecarpus anacardium, Amura rohitaka, 
Glycyrrhiza glabra and copper powder were 
reported to inhibit breast tumour development in 
mice by significantly extending the survival period. 
This drug was also found to be efficient in clinical 
trials. Experimental study carried out with this drug 
on 100 young female mice, each 50 were allocated 
under trial and control groups. Trial group mice 
revealed a significant inhibition of the rate of 
development of tumour in comparison to control 
group; showed survival period up to 50 – 60 days in 
relation to the 100% mortality within 20-30 days in 
control group.  
 Clinical study also carried out under five 
groups Group-I with Chemo+Radio+Ayurvedic trial 
drugs; Group-II with Chemo+Radio therapy, Group-
III with Chemotherapy+Ayurvedic trial drugs, 
Group-IV with Chemotherapy alone and Group-V 
with Ayurvedic trial drug alone. Complete response 
was observed in Chemo+Radio therapy+Ayurvedic 
trial drug group37. 
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CONCLUSION 
 After studying pharmacological studies and 
clinical trials  on single herbal drugs, compound 
herbo-mineral drugs it can be concluded that; 
1. There is a hope for the development of 
comprehensive Ayurvedic regimen for the cure 
of early stage of Cancer  
2. To obtain strong curative effect, 
pharmacological and clinical trials are need to 
be carried out with Vishavarga drugs as well as 
metallic Visha drugs like Haritala, Manahshila, 
Gouripashana etc.  
3. Extensive Clinical trials are to be carried out 
with the pharmacologically proved herbal, 
herbo-mineral compound drugs.  
4. Ayurvedic are also found effective in preventing 
the gynecological cancers through reversing 
cytological changes that occurring in the target 
organs for example – low grade cervical 
intraepithelial neoplasia. 
5. Some drugs like Haridra are effective in 
reducing the Chemotherapy/radiotherapy 
induced side effects and enhancing the 
bioavailability of the drugs. 
6. Another important aspect of Cancer 
management is improvement of quality of life; 
in this direction studies are going on, results are 
yet be published.  
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